Page 8 - அகஸ்டா பல்கலைக்கழகம் மருத்துவ கல்லூரி ஆஃப் ஜார்ஜியா News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from அகஸ்டா பல்கலைக்கழகம் மருத்துவ கல்லூரி ஆஃப் ஜார்ஜியா. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In அகஸ்டா பல்கலைக்கழகம் மருத்துவ கல்லூரி ஆஃப் ஜார்ஜியா Today - Breaking & Trending Today

ASCO GU 2021: Best of Journals: Prostate Cancer

Published 13 February 2021
(UroToday.com) The 2021 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium included a prostate cancer session Best of Journals with Dr. Keyan Salari providing the surgical perspective. Dr. Salari selected two studies assessing active surveillance in Black men with low-risk prostate cancer, and one study assessing the timing of radiation therapy after radical prostatectomy.
The first paper was by Deka et al. “Association Between African American Race and Clinical Outcomes in Men Treated for Low-Risk Prostate Cancer with Active Surveillance” published in the
Journal of the American Medical Association (JAMA).
1 Dr. Salari notes that there has been lower uptake of active surveillance among Black men, potentially leading to an increased burden of treatment-related side-effects. As we learn more about active surveillance, it is important to ensure that all members of the population are able to take adv ....

United States , Zachary Klaassen , Keyan Salari , Prostate Cancer Genetics Program , American Society Of Clinical Oncology , Augusta University Medical College Of Georgia , Harvard Medical School , Journal Of The American Medical Association , Veterans Health Administration , Gleason Grade Group , Georgia Cancer Center , Association Between African American Race , Clinical Oncology , Cancers Symposium , Between African American Race , Clinical Outcomes , Men Treated , Low Risk Prostate Cancer , American Medical Association , Health Administration Care System , African American , Hispanic White , Among African American , American Race , Not Associated , Active Surveillance ,

ASCO GU 2021: Invited Discussion: Enfortumab Vedotin in Previously Treated Urothelial Cancer

Published 13 February 2021
(UroToday.com) The ASCO GU 2021 Genitourinary Cancers Symposium annual meeting included an invited discussion from Dr. Arlene Siefker-Radtke discussing “Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma” and “EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors.”
Dr. Siefker-Radtke notes that we now have level 1 evidence with overall survival benefit for enfortumab vedotin in the 3
rd line for metastatic urothelial carcinoma. EV-301 (NCT03474107) is a global, open-label phase III study of enfortumab vedotin versus chemotherapy conducted in patients with locally advanced or metastatic urothelial carcinoma who had received prior platinum-containing chemotherapy and had disease progression during or afte ....

United States , Zachary Klaassen , Arlene Siefker Radtke , Arleneo Siefker Radtke , University Of Texas Md Anderson Cancer Center , Georgia Cancer Center , Augusta University Medical College Of Georgia , Cancers Symposium , Cancer Center , Urologic Oncologist , Assistant Professor , Medical College , Clinical Oncology Genitourinary Cancers Symposium , ஒன்றுபட்டது மாநிலங்களில் , சக்கரி க்லாஸ்சேங் , பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் ம்ட் ஆண்டர்சன் புற்றுநோய் மையம் , ஜார்ஜியா புற்றுநோய் மையம் , அகஸ்டா பல்கலைக்கழகம் மருத்துவ கல்லூரி ஆஃப் ஜார்ஜியா , புற்றுநோய்கள் சிம்போசியம் , புற்றுநோய் மையம் , சிறுநீரக புற்றுநோயியல் நிபுணர் , உதவியாளர் ப்ரொஃபெஸர் , மருத்துவ கல்லூரி ,

ASCO GU 2021: Invited Discussion: Testicular Seminoma

ASCO GU 2021 Genitourinary Cancers Symposium, Imaging modality and frequency in surveillance of stage I seminoma testicular cancer: Results from a randomized, phase III, factorial trial (TRISST), Testicular Seminoma. ....

United States , Noord Holland , Pilar Laguna , Zachary Klaassen , Georgia Cancer Center , University Of Amsterdam , Augusta University Medical College Of Georgia , Cancers Symposium , Urologic Oncologist , Assistant Professor , Medical College , Clinical Oncology Genitourinary Cancers Symposium , ஒன்றுபட்டது மாநிலங்களில் , நூற்த் ஹாலண்ட் , பைலர் லகுனா , சக்கரி க்லாஸ்சேங் , ஜார்ஜியா புற்றுநோய் மையம் , பல்கலைக்கழகம் ஆஃப் ஆம்ஸ்டர்டாம் , அகஸ்டா பல்கலைக்கழகம் மருத்துவ கல்லூரி ஆஃப் ஜார்ஜியா , புற்றுநோய்கள் சிம்போசியம் , சிறுநீரக புற்றுநோயியல் நிபுணர் , உதவியாளர் ப்ரொஃபெஸர் , மருத்துவ கல்லூரி ,

ASCO GU 2021: Alignment and Discordances in Perceptions and Experiences of Shared Decision Making Among Bladder Cancer Patients and Their Care Team

SHARE
ASCO GU 2021: Alignment and Discordances in Perceptions and Experiences of Shared Decision Making Among Bladder Cancer Patients and Their Care Team
Published 13 February 2021
(UroToday.com) Shared decision-making regarding cancer treatment is critical. In previous PRIME educational programs involving patients with bladder cancer and their care teams, effective shared decision-making was found to be integral to the development of treatment plans that reflected patient preferences and treatment goals. However, oncology care teams face complex barriers that impede their ability to personalize bladder cancer therapy for each patient. PRIME conducted a Collaborative Learning Program in five US healthcare systems to support communication and shared decision-making between patients with bladder cancer and their urology/medical oncology teams to improve outcomes and quality of life for these patients. At the 2021 American Society of Clinical Oncology (ASCO) Genitouri ....

United States , Zachary Klaassen , Los Angeles , Karim Chamie , American Society Of Clinical Oncology , Department Of Urology , David Geffen School Of Medicine , Georgia Cancer Center , Collaborative Learning Program , Augusta University Medical College Of Georgia , Clinical Oncology , Cancers Symposium , David Geffen School , Urologic Oncologist , Assistant Professor , Medical College , Clinical Oncology Genitourinary Cancers Symposium , ஒன்றுபட்டது மாநிலங்களில் , சக்கரி க்லாஸ்சேங் , லாஸ் ஏஞ்சல்ஸ் , அமெரிக்கன் சமூகம் ஆஃப் மருத்துவ புற்றுநோயியல் , துறை ஆஃப் சிறுநீரகம் , டேவிட் கெஃப்ஃபெந் பள்ளி ஆஃப் மருந்து , ஜார்ஜியா புற்றுநோய் மையம் , கூட்டு கற்றல் ப்ரோக்ர்யாம் , அகஸ்டா பல்கலைக்கழகம் மருத்துவ கல்லூரி ஆஃப் ஜார்ஜியா ,

ESOU 2021: ESUR Lecture: Genetic Testing for Prostate Cancer: When and How?

ESOU 2021: ESUR Lecture: Genetic Testing for Prostate Cancer: When and How?
(UroToday.com) At the 2021 European Association of Urology (EAU) Section of Oncological Urology (ESOU) Virtual Annual Meeting, the EAU Section of Urological Research (ESUR) lecture was provided by Dr. Karen Knudsen discussing when and how to provide genetic testing for prostate cancer. Dr. Knudsen pointed out that there is an extraordinary burden of prostate cancer in the US, ranked as #1 for males in estimated new cases and #2 in estimated cancer-related deaths. Germline testing is revolutionizing care, with 12-17% of metastatic patients having germline mutations and 5-7% of early-stage patients having germline mutations. As such, germline testing is impacting precision medicine and tailored screening approaches, which also has an impact on families for hereditary cancer risk. ....

United States , Veda Giri , Zachary Klaassen , Karen Knudsen , European Association Of Urology , Sidney Kimmel Cancer Center , Jefferson Health System , Augusta University Medical College Of Georgia , Jefferson Health Enterprise , Georgia Cancer Center , Grade Group , Section Of Urological Research , Oncology Services , National Comprehensive Cancer Network , Oncological Urology , Virtual Annual Meeting , Neurological Research , Philadelphia Consensus Conference , Genetic Testing , Inherited Prostate Cancer Risk , Philadelphia Prostate Cancer Consensus Conference , Germline Testing , Prostate Cancer , Familial High Risk Assessment , Prostate Cancer Version , Executive Vice President ,